STXBP1 Encephalopathy — Preclinical Gene Therapy Program
📖 Wiki Page
clinical977 wordssynced 2026-04-02
Executive Summary
STXBP1 encephalopathy (also known as Early Infantile Epileptic Encephalopathy 5, EIEE5, or STXBP1-E) is a devastating neurodevelopmental disorder caused by pathogenic variants in the [STXBP1 gene](/genes/stxbp1), which encodes Munc18-1 — a critical synaptic protein required for neurotransmitter release. Unlike many genetic epilepsies, there are currently no disease-modifying therapies specifically targeting the underlying genetic cause. Several academic groups are actively developing AAV-based gene therapy approaches for STXBP1, representing a potential breakthrough for this devastating condition.
[STXBP1](/genes/stxbp1) encephalopathy is one of the most common genetic epileptic encephalopathies, accounting for approximately 5-10% of EIEE cases. Key clinical features include:
...
Executive Summary
STXBP1 encephalopathy (also known as Early Infantile Epileptic Encephalopathy 5, EIEE5, or STXBP1-E) is a devastating neurodevelopmental disorder caused by pathogenic variants in the [STXBP1 gene](/genes/stxbp1), which encodes Munc18-1 — a critical synaptic protein required for neurotransmitter release. Unlike many genetic epilepsies, there are currently no disease-modifying therapies specifically targeting the underlying genetic cause. Several academic groups are actively developing AAV-based gene therapy approaches for STXBP1, representing a potential breakthrough for this devastating condition.
[STXBP1](/genes/stxbp1) encephalopathy is one of the most common genetic epileptic encephalopathies, accounting for approximately 5-10% of EIEE cases. Key clinical features include:
Onset: First year of life (typically 1-12 months, median ~6 months)
Seizure types:
Infantile spasms (West syndrome)
Focal seizures
Tonic-clonic seizures
Myoclonic seizures
Early myoclonic encephalopathy
EEG findings: Burst-suppression pattern in ~50% of cases
Development: Normal at birth, followed by developmental stagnation and regression
Core symptoms:
Severe intellectual disability
Movement disorders (ataxia, dystonia, choreoathetosis)
Hypotonia
Microcephaly in many cases
Prognosis: Severe, with ongoing seizures and significant developmental impairment
Epidemiology
Incidence: ~1 in 100,000-150,000 live births
Prevalence: Estimated 500-1,000 patients in the US
Inheritance: Autosomal dominant (de novo variants common)
Gender distribution: Slight female predominance due to reduced male viability
Molecular Mechanism
STXBP1 encodes Munc18-1, a synaptic protein essential for neurotransmitter release:
Normal function: Munc18-1 binds to syntaxin-1 and facilitates SNARE complex assembly
Role in excitability: Proper SNARE-mediated vesicle release regulates inhibitory neurotransmission
Pathogenic mechanism: Loss-of-function variants reduce synaptic transmission, leading to hyperexcitability
Therapeutic hypothesis: Restoring STXBP1 expression could restore synaptic function and reduce seizures
Gene Therapy Approach
Vector Design
| Component | Design Consideration | |-----------|-----------------| | Promoter | Synapsin or CamKIIa for neuron-specific expression | | Transgene | Full-length human STXBP1 coding sequence | | Introns | Synthetic intron for proper expression | | PolyA | bGH or SV40 polyA signal | | Serotype | AAV9 or AAV-PHP.eB for CNS penetration |
Preclinical Data Requirements
1. Proof-of-Concept Studies
| Study | Model | Readout | Status | |-------|-------|--------|--------| | AAV-STXBP1 in Stxbp1+/− mice | Heterozygous mouse model | Seizure frequency, behavior | Ongoing | | AAV-STXBP1 in iPSC-derived neurons | Human neurons | Electrophysiology | Research | | Dose-ranging study | Wild-type mice | Biodistribution, expression | Completed |
2. IND-Enabling Studies Required
| Study | Purpose | Timeline | |-------|--------|---------| | GLP toxicology (rodent) | Safety assessment | Required | | GLP toxicology (NHP) | Safety in relevant species | Required | | Biodistribution | Tissue distribution | Required | | Driver line safety | Inclusion in CTA | Required |